In partnership with
And we’re sure you have, 2025’s been a solid year for tech and biotech, with some strong IPO debuts keeping the momentum alive.
Of course, it’s been nothing like the 2021 frenzy, but IPO volume wise, it’s been the best year since.
Looking ahead to 2026, though, the stage is set for a bigger splash. Potentially hundreds of listings as inflation hopefully continues to cool, interest rates hold steady (or trim), and unicorns in private markets are ready to cash in.
Economic tailwinds and AI buzz are pushing companies out of the shadows, though geopolitics and mid-term election vibes could stir some turbulence.
Still, the outlook’s bright. Let’s dive into what’s coming, with tech and biotech leading the charge, plus a few other sectors ready to shine.
Tech’s poised to dominate again, building on 2025’s momentum. AI and data analytics are the big drivers.
Databricks, with its big data and machine learning tools, is a prime candidate for a 2026 IPO, sitting pretty at a $40 billion valuation.
Their enterprise platforms are a hit as companies scramble to harness AI, and their debut could be massive.
Canva, the design platform that’s made visuals a breeze, is also eyeing a public jump, potentially valued at $26 billion.
Their freemium model has hooked everyone from freelancers to big brands. Tech’s all about growth, and these names are wired to deliver.
Biotech’s not far behind, coming off a strong 2025 where funding rebounded and pipelines advanced.
After a lean few years, we’re looking at 30 to 40 IPOs in 2026 in the sector, per J.P. Morgan’s take.
Inflammation and immunology are leading the pack, with companies targeting eczema and other autoimmune issues through non-steroid drugs that hit massive market needs.
In neuroscience, players are pushing frontiers with trials for rare brain disorders, where orphan-drug status could inflate values big time.
Meanwhile, the anti-obesity space is buzzing, surfing the GLP-1 craze sparked by Ozempic with new candidates that could tap into $10 billion markets.
Biotech’s volatile, but 2026’s winners could be life-changing for investors. So, we’ll be paying very close attention, obviously.
How High-Net-Worth Families Invest Beyond the Balance Sheet
Every year, Long Angle surveys its private member community — entrepreneurs, executives, and investors with portfolios from $5M to $100M — to understand how they allocate their time, money, and trust.
The 2025 High-Net-Worth Professional Services Report reveals what today’s wealthy families value most, what disappoints them, and where satisfaction truly comes from.
From wealth management to wellness, from private schools to personal trainers — this study uncovers how the top 1% make choices that reflect their real priorities. You’ll see which services bring the greatest satisfaction, which feel merely transactional, and how spending patterns reveal what matters most to affluent households.
Benchmark your household’s service spending against peers with $5–25M portfolios.
Learn why emotional well-being often outranks financial optimization.
See which services families are most likely to change — and which they’ll never give up.
Understand generational differences shaping how the wealthy live, work, and parent.
See how your spending, satisfaction, and priorities compare to your peers. Download the report here.
Fintech’s the potential sleeper-hit to watch. Post 2025, with some big names showing the way, the sector could see more digital banking and crypto-adjacent plays emerge.
Liquidity’s the key: private equity’s flush, M&A’s buzzing, and tech’s 36% or so S&P weight has investors craving new names.
A market hiccup could spook things, but 2026’s looking like a hot ticket. So, keep an eye out; the IPO wave’s about to hit!
What ties it all together?
Investors are betting on innovation in a world where AI and health tech solve real problems, from data overload to chronic diseases.
Sure, valuations might get frothy, and not every debut will stick the landing, but remember, markets love a good story… however, they do demand results, eventually.
If rates stay friendly and consumer spending holds, we could see a surge that rivals the best years. Have a look at that chart above again. 2026, although unlikely to rival 2021, could end up close to 2020’s IPO volume.
For those playing the long game, diversifying across tech giants like Databricks and emerging biotech upstarts could pay off handsomely.
As we wrap up 2025, the setup for next year feels electric—grab your spot before the listings flood in…
By upgrading your account to IPO Stream Premium.
Happy Thanksgiving,
Tim
